A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations

Affiliations

• ¹ Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
• ² Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, Hunan, P. R. China.
• ³ Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
• ⁴ Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, P. R. China.
• ⁵ Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, P. R. China.
• ⁶ Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.
• ⁷ Department of Medical Thoracic Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, Zhejiang, P. R. China.
• ⁸ Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.
• ⁹ Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, P. R. China.
• ¹⁰ Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China.
• ¹¹ Huadong Global Development Center, Hangzhou ZhongMei HuaDong Pharmaceutical Company, Hangzhou, Zhejiang, P. R. China.
• ¹² Department of Respiratory Medicine, General Hospital of Eastern Theater Command, Nanjing, Jiangsu, P. R. China.
• ¹³ Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, P. R. China.